Anemia of chronic renal disease as well as cancer and chemotherapy‐induced anemia (CIA) are often associated with poor outcomes, and the use of erythropoietin stimulating agents (ESAs) for patients with chronic kidney disease (CKD) and anemia associated with cancer has been a common practice. The gene discussed is EPO; the disease is chronic kidney disease.